Relationship between Cardiac Geometry and Serum Hepcidin in Chronic Kidney Disease: Analysis from the KNOW-CKD Study

Hyang Ki Min1, Yun Kyu Oh2, Kyu Hun Choi3

  • 1Division of Nephrology, Department of Internal Medicine, Nowon Eulji Medical Center, Eulji University School of Medicine, Seoul, Korea.

Insights

Increased cardiac relative wall thickness (RWT) is linked to higher serum hepcidin in chronic kidney disease (CKD) patients, especially women and those with low transferrin saturation (TSAT). Further research is needed to confirm this association.

Area of Science:

  • Nephrology
  • Cardiology
  • Biochemistry

Background:

  • Limited research exists on the connection between cardiac function/geometry and serum hepcidin in chronic kidney disease (CKD).
  • Understanding this relationship is crucial for managing CKD patients, who often have complex cardiovascular and metabolic issues.

Purpose of the Study:

  • To investigate the association between cardiac function and geometry and serum hepcidin levels in a large cohort of CKD patients.
  • To identify specific cardiac parameters linked to elevated hepcidin in this population.

Main Methods:

  • Analysis of data from 1,897 patients in a multicenter prospective Korean study.
  • Logistic regression analysis, including univariate and multivariate models, to assess relationships between cardiac measures and serum hepcidin.
  • Subgroup analyses were performed to explore associations in specific patient demographics and conditions.

Main Results:

  • While ejection fraction (EF) and E/e' were not associated with hepcidin, increased relative wall thickness (RWT) and left ventricular mass index (LVMI) showed univariate associations.
  • In multivariate analysis, a 0.1-unit increase in RWT independently predicted higher odds of elevated serum hepcidin (OR, 1.989; P < 0.001).
  • This independent association was significant in women and patients with low transferrin saturation (TSAT).

Conclusions:

  • Increased cardiac relative wall thickness (RWT) is independently associated with higher serum hepcidin levels in CKD patients.
  • This association is particularly pronounced in women and individuals with low TSAT.
  • Further studies are warranted to elucidate the causal relationship and clinical implications of cardiac geometry and hepcidin in CKD.
Abstract

Related Concept Videos

Drug Dosing in Renal Diseases: Estimation of Glomerular Filtration Rate Based on Serum Creatinine Concentration01:28

Drug Dosing in Renal Diseases: Estimation of Glomerular Filtration Rate Based on Serum Creatinine Concentration

Glomerular filtration rate (GFR) can be estimated from serum creatinine using the modification of diet in renal disease (MDRD) formula or the chronic kidney disease–epidemiology collaboration (CKD–EPI) equation. Both methods are widely used in clinical practice to assess kidney function and guide treatment decisions.The MDRD equation does not require weight or height measurements and is normalized to the body surface area of 1.73 m², considered the average adult surface area.
135
Chronic Kidney Disease II: Clinical Manifestations01:24

Chronic Kidney Disease II: Clinical Manifestations

Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
486
Chronic Kidney Disease III: Interprofessional Care01:28

Chronic Kidney Disease III: Interprofessional Care

Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
293
Chronic Kidney Disease I: Introduction01:25

Chronic Kidney Disease I: Introduction

Chronic Kidney Disease (CKD) arises when the kidneys progressively lose their ability to function, ultimately leading to end-stage renal disease. At this advanced stage, the kidneys can no longer filter waste or maintain essential body functions, requiring renal replacement therapy (RRT) through dialysis or a kidney transplant for survival.Early-stage chronic kidney disease and detection challengesIn CKD's early stages, symptoms often remain absent because healthy nephrons compensate for...
505
Chronic Kidney Disease IV: Nursing Management01:18

Chronic Kidney Disease IV: Nursing Management

Nursing management is essential for preventing complications, maintaining stability, and improving patients' quality of life in chronic kidney disease (CKD). By using a structured approach, nurses help slow CKD progression and support effective patient care​.1. Comprehensive patient assessmentEffective management begins with nurses reviewing the patient’s medical history, and identifying key risk factors like diabetes, hypertension, and nephrotoxic drug use. Nurses assess signs of...
252
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
174